Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters. — VialBase Research
Real-world evidence that tirzepatide effectively lowers HbA1c and body weight in adults 65 and older, provided concomitant secretagogues are pre-emptively reduced to avoid hypoglycemia.
- Secondary analysis of the Hokkaido-TZP study in patients aged 65 and older; 213 in the safety set, with 11 (5.2%) discontinuing due to adverse events, primarily gastrointestinal
- In the effectiveness set (n=199; mean age 71.3 years, baseline HbA1c 7.79%), tirzepatide significantly reduced both HbA1c and BMI over 6 months in Young-old (65-74) and Old-old (75+) groups
- Among 148 patients (74.4%) using hypoglycemia-risk agents (insulin, sulfonylureas, or glinides), 66.9% achieved HbA1c <7.0% and no severe hypoglycemia was reported
- Physicians proactively reduced concomitant secretagogues in 39.2% of users, yet this subgroup still achieved HbA1c reductions comparable to the whole cohort
- Weight loss was more pronounced in GLP-1 receptor agonist-naive patients and those on fewer hypoglycemia-inducing agents; tirzepatide dose tended to be lower in those with greater weight loss
Summary
This real-world secondary analysis of the Hokkaido-TZP study evaluated tirzepatide outcomes in patients with type 2 diabetes aged 65 years and older, focusing on hypoglycemia risk and weight-loss parameters. Across the safety analysis set of 213 patients and an effectiveness set of 199 (mean age 71.3 years, baseline HbA1c 7.79%), tirzepatide significantly reduced both HbA1c and BMI over 6 months in Young-old and Old-old subgroups. Effectiveness was preserved even among patients on hypoglycemia-inducing agents when concomitant medications were proactively adjusted, and no severe hypoglycemia was reported.
Key Findings
- Of 213 patients in the safety analysis set, 11 (5.2%) discontinued treatment because of adverse events, primarily gastrointestinal symptoms.
- Effectiveness set (n=199; mean age 71.3 years, baseline HbA1c 7.79%): significant reductions in HbA1c and BMI over 6 months in both Young-old (65-74 years) and Old-old (75+ years) groups.
- Among the 148 patients (74.4%) using agents associated with hypoglycemia risk (insulin, sulfonylureas, or glinides) at baseline, 66.9% achieved HbA1c <7.0%.
- Physicians proactively adjusted concomitant medications in 39.2% of those users; despite these pre-emptive reductions, the subgroup still achieved HbA1c reductions comparable to the entire cohort, with no severe hypoglycemia reported.
- Body weight reduction was more pronounced in GLP-1 receptor agonist-naive patients and those taking fewer hypoglycemia-inducing agents; tirzepatide dose tended to be lower in patients who achieved greater weight loss.
Relevance to Tirzepatide
This study provides practical real-world guidance for using tirzepatide in an older, often polypharmacy-burdened population that is typically underrepresented in pivotal trials. It shows that the dual GIP/GLP-1 agonist retains strong glycemic and weight efficacy in patients aged 65 and older, but that safety hinges on pre-emptively reducing concomitant secretagogues such as insulin and sulfonylureas to avoid excessive HbA1c and weight loss. The greater weight response in GLP-1 receptor agonist-naive patients (relevant when transitioning from agents like Semaglutide) and the inverse dose-response pattern for weight loss are useful signals for individualized titration in geriatric care.
Citation
Kitsunai H, Maruyama F, Miyano Y, et al. Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters. Endocrine journal. 2026. doi:10.1507/endocrj.EJ26-0246.
See Also
- Parent compound: Tirzepatide
- Semaglutide
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.